Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewAll 14 reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
We recorded what eight GLP-1 sellers charged, every day, from January to August. One of them actually changed its price. Three other movements in our own chart were us correcting what we had been counting as a price.
Since January we have recorded what a GLP-1 costs at the sellers we track, one reading per seller per day, and kept every reading. That is 550 data points across fifteen provider-product series, from 6 January to 22 August 2026. This article is what the series says.
The short version is not the one we expected to write. Across eight months, one seller changed its price. Three other movements visible in our own chart were not the market moving at all — they were us correcting what we had been treating as a price. That second finding turns out to be the more useful one for anyone about to buy.
On 19 August, Mochi Health cut the medication half of its compounded offering. Semaglutide went from $99 to $60 a month, tirzepatide from $199 to $90. Mochi requires a $79 monthly membership and states plainly that medication is not included in it, so the all-in monthly figure moved from $178 to $139 for semaglutide and from $278 to $169 for tirzepatide - a 22% and a 39% cut.
That made Mochi the cheapest tirzepatide in our table, below Maximus at $215 all-in. The same page picked up a qualifier it had not carried before: "Price varies based on the dose your provider prescribes." So the $60 and $90 are the bottom rungs of a dose-based ladder, not a flat rate. We caught the change on a scheduled re-read; it was not announced.
One series in our data does not change price - it stops. Hims sold compounded semaglutide at $199 all-in through 13 February, and from 30 March the same page sells a branded Wegovy pen at $348. Between those dates the compounded line simply ends.
That is a $149 jump for the same molecule, and it is the clearest illustration in the dataset of what happens when a compounded route closes: the price a buyer sees is not adjusted, it is replaced by a different product. Anyone quoting a 2026 compounded-semaglutide price from memory is quoting a market that no longer exists at that seller.
The other three movements in the chart deserve to be labelled honestly, because each one looks like a price change and is not.
TrimRx, 19 August: $179 to $299. TrimRx did not raise its price by 67%. Its homepage card advertises $179, its terms page prices the follow-up consultation - the ongoing month - at $299, and the $179 is a first-month rate. We had been recording the advertised figure. The tirzepatide row moved $259 to $399 for the same reason.
Maximus, 4 August: $149.99 to $126.10. Maximus bills per 28-day supply, not per calendar month. We had been reading $116 as a monthly figure; converted properly, 28 days at $116 is $126.10 a month. The provider changed nothing.
Ro, 4 August: $494 to $498. Ro charges $349 for a Wegovy pen plus a $149 membership on the one-month plan. The four-dollar move is our shift from an entry figure to the ongoing one. Nothing on Ro's side moved.
Every one of those corrections runs in the same direction: the number a seller puts in front of you is lower than the number you keep paying. First-month rates, 28-day cycles priced as months, memberships quoted separately from medication. None of it is hidden - all four figures above come from the sellers' own pages and terms - but all of it requires reading past the card.
This is why our ledger records an ongoing, all-in figure and excludes promotional first months. It is also why a price comparison assembled from homepages is close to meaningless: three of our four largest "movements" this year came from exactly that mistake, made by us, and corrected only because someone opened the terms page.
The branded anchors held flat for the entire period. NovoCare's Wegovy cash price stayed at $349 and LillyDirect's Zepbound at $299 from the day each entered our series. Hims branded stayed at $348 and $448, Ro at $349 and $299 before membership, Henry Meds at $179 from March to August without a single change.
So the volatility in this market is not where the headlines suggest. The manufacturers' direct-to-consumer prices are stable. The movement is in the compounded tier, and in August it moved down at one seller and stayed put at every other.
One reading per seller per day, taken from the seller's own page or terms, recorded with the date it was read and the sentence it was read from. Where a seller blocks automated requests we use the Internet Archive's capture of the same page. Prices are normalised to an ongoing monthly, all-in figure: medication plus any mandatory membership, excluding promotional first months and discount codes.
The limits are worth stating. Fifteen series is not the market - it is eight sellers and two molecules. A "lowest rung" price on a dose-based ladder is not what a patient on a higher dose pays. And our own three corrections this year are evidence that a figure can sit in a dataset for months before someone notices it was the wrong figure.
This article is a reading of the record at one moment. The record itself is kept at the price history, which lists every change as it happens and publishes the underlying daily readings as a file anyone can open; what things cost right now is on the price tracker.
Of the sellers we track, Mochi Health at $139 a month all-in for compounded semaglutide and $169 for compounded tirzepatide, after its 19 August cut. Both figures include the $79 membership Mochi requires and both are the lowest rung of a dose-based ladder.
At the sellers we track, prices were flat from January to August with one exception: Mochi cut compounded semaglutide 22% and compounded tirzepatide 39% on 19 August. Branded cash prices at NovoCare and LillyDirect did not change at all.
Because advertised figures are frequently first-month rates, exclude a mandatory membership, or price a 28-day supply as a month. We record what an ongoing month costs with everything required to get the medication included, which is usually higher than the card on the homepage.
Our own daily readings of each seller's published pricing, kept since January 2026 with the date and quoted sentence for every entry. The current snapshot is on our price index.
Editorial note: PeptideWellness takes no payment from any seller named here. Prices were read from each seller's own published pages on the dates given and are reproduced without adjustment.